pradefovir

Pradefovir is a liver-targeted, orally administered small molecule prodrug of adefovir, designed for the treatment of chronic hepatitis B virus (HBV) infection. It belongs to a novel series of phosphate and phosphonate prodrugs that are specifically activated in the liver by cytochrome P450 3A4 (CYP3A4), resulting in higher concentrations in hepatic tissue and reduced exposure to other organs such as the kidneys. After activation, pradefovir is converted to adefovir, which is then phosphorylated by cellular kinases into its active diphosphate form. This active metabolite competes with dATP and is incorporated into viral DNA by HBV DNA polymerase, causing chain termination and inhibition of viral replication. Pradefovir has demonstrated efficacy comparable to tenofovir disoproxil fumarate with an improved safety profile due to lower nephrotoxicity risk[1][2][3][6].

Brand names

Hepavir-B

Other names

pradefovir mesylateremofovir mesylate